camrelizumab

Association of Alpha-Fetoprotein and Clinical Outcomes in Patients with Unresectable Hepatocellular Carcinoma Treated with First-Line Camrelizumab Plus Rivoceranib vs Sorafenib: Post Hoc Exploratory Analysis of the CARES-310 Trial